Nintedanib (BIBF 1120) a szolid daganatok kezelésében: Biológia és klinikai tapasztalatok áttekintése

Translated title of the contribution: Nintedanib (BIBF 1120) in the treatment of solid cancers: An overview of biological and clinical aspects

Szilvia Török, Mihály T. Cserepes, Ferenc Rényi-Vámos, B. Döme

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Angiogenesis is essential for tumor growth and metastasis. The main regulators of the process are the signaling cascades of VEGF-, PDGF- and FGF receptors. Inhibition of these pathways holds potential therapeutic benefit not only for cancer patients, but also for the treatment of other diseases. This paper summarizes the experimental and clinical results of studies available so far on the multi-target tyrosine kinase inhibitor nintedanib (BIBF 1120). According to these studies, nintedanib effectively inhibits VEGFR-, PDGFR- and FGFR signalization and thus the proliferation and survival of cell types which highly express these receptors (i.e. endothelial and smooth muscle cells and pericytes). In vitro studies and in vivo xenograft experiments have provided promising results. In the clinical setting, BIBF 1120 seems to be effective and well tolerated in various tumor types, such as lung, prostate, colorectal and hepatocellular carcinoma, as well as in gynecological tumors. The main adverse events are gastrointestinal toxicities and the reversible elevation of liver enzyme levels. Nintedanib might also be combined with paclitaxel, carboplatin, pemetrexed and docetaxel. There are several ongoing clinical trials testing the efficacy of BIBF 1120.

Original languageHungarian
Pages (from-to)199-208
Number of pages10
JournalMagyar Onkologia
Volume56
Issue number3
Publication statusPublished - 2012

Fingerprint

Neoplasms
docetaxel
Pemetrexed
Therapeutics
Platelet-Derived Growth Factor Receptors
Fibroblast Growth Factor Receptors
Pericytes
Vascular Endothelial Growth Factor Receptor
Carboplatin
Paclitaxel
Heterografts
Protein-Tyrosine Kinases
Smooth Muscle Myocytes
nintedanib
Prostate
Hepatocellular Carcinoma
Colorectal Neoplasms
Cell Survival
Cell Proliferation
Clinical Trials

ASJC Scopus subject areas

  • Oncology

Cite this

Nintedanib (BIBF 1120) a szolid daganatok kezelésében : Biológia és klinikai tapasztalatok áttekintése. / Török, Szilvia; Cserepes, Mihály T.; Rényi-Vámos, Ferenc; Döme, B.

In: Magyar Onkologia, Vol. 56, No. 3, 2012, p. 199-208.

Research output: Contribution to journalArticle

Török, Szilvia ; Cserepes, Mihály T. ; Rényi-Vámos, Ferenc ; Döme, B. / Nintedanib (BIBF 1120) a szolid daganatok kezelésében : Biológia és klinikai tapasztalatok áttekintése. In: Magyar Onkologia. 2012 ; Vol. 56, No. 3. pp. 199-208.
@article{bec2cb43a70f4083b396242d7e5dc874,
title = "Nintedanib (BIBF 1120) a szolid daganatok kezel{\'e}s{\'e}ben: Biol{\'o}gia {\'e}s klinikai tapasztalatok {\'a}ttekint{\'e}se",
abstract = "Angiogenesis is essential for tumor growth and metastasis. The main regulators of the process are the signaling cascades of VEGF-, PDGF- and FGF receptors. Inhibition of these pathways holds potential therapeutic benefit not only for cancer patients, but also for the treatment of other diseases. This paper summarizes the experimental and clinical results of studies available so far on the multi-target tyrosine kinase inhibitor nintedanib (BIBF 1120). According to these studies, nintedanib effectively inhibits VEGFR-, PDGFR- and FGFR signalization and thus the proliferation and survival of cell types which highly express these receptors (i.e. endothelial and smooth muscle cells and pericytes). In vitro studies and in vivo xenograft experiments have provided promising results. In the clinical setting, BIBF 1120 seems to be effective and well tolerated in various tumor types, such as lung, prostate, colorectal and hepatocellular carcinoma, as well as in gynecological tumors. The main adverse events are gastrointestinal toxicities and the reversible elevation of liver enzyme levels. Nintedanib might also be combined with paclitaxel, carboplatin, pemetrexed and docetaxel. There are several ongoing clinical trials testing the efficacy of BIBF 1120.",
keywords = "Angiogenesis, BIBF 1120, Receptor tyrosine kinase inhibitors, Solid tumors",
author = "Szilvia T{\"o}r{\"o}k and Cserepes, {Mih{\'a}ly T.} and Ferenc R{\'e}nyi-V{\'a}mos and B. D{\"o}me",
year = "2012",
language = "Hungarian",
volume = "56",
pages = "199--208",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "3",

}

TY - JOUR

T1 - Nintedanib (BIBF 1120) a szolid daganatok kezelésében

T2 - Biológia és klinikai tapasztalatok áttekintése

AU - Török, Szilvia

AU - Cserepes, Mihály T.

AU - Rényi-Vámos, Ferenc

AU - Döme, B.

PY - 2012

Y1 - 2012

N2 - Angiogenesis is essential for tumor growth and metastasis. The main regulators of the process are the signaling cascades of VEGF-, PDGF- and FGF receptors. Inhibition of these pathways holds potential therapeutic benefit not only for cancer patients, but also for the treatment of other diseases. This paper summarizes the experimental and clinical results of studies available so far on the multi-target tyrosine kinase inhibitor nintedanib (BIBF 1120). According to these studies, nintedanib effectively inhibits VEGFR-, PDGFR- and FGFR signalization and thus the proliferation and survival of cell types which highly express these receptors (i.e. endothelial and smooth muscle cells and pericytes). In vitro studies and in vivo xenograft experiments have provided promising results. In the clinical setting, BIBF 1120 seems to be effective and well tolerated in various tumor types, such as lung, prostate, colorectal and hepatocellular carcinoma, as well as in gynecological tumors. The main adverse events are gastrointestinal toxicities and the reversible elevation of liver enzyme levels. Nintedanib might also be combined with paclitaxel, carboplatin, pemetrexed and docetaxel. There are several ongoing clinical trials testing the efficacy of BIBF 1120.

AB - Angiogenesis is essential for tumor growth and metastasis. The main regulators of the process are the signaling cascades of VEGF-, PDGF- and FGF receptors. Inhibition of these pathways holds potential therapeutic benefit not only for cancer patients, but also for the treatment of other diseases. This paper summarizes the experimental and clinical results of studies available so far on the multi-target tyrosine kinase inhibitor nintedanib (BIBF 1120). According to these studies, nintedanib effectively inhibits VEGFR-, PDGFR- and FGFR signalization and thus the proliferation and survival of cell types which highly express these receptors (i.e. endothelial and smooth muscle cells and pericytes). In vitro studies and in vivo xenograft experiments have provided promising results. In the clinical setting, BIBF 1120 seems to be effective and well tolerated in various tumor types, such as lung, prostate, colorectal and hepatocellular carcinoma, as well as in gynecological tumors. The main adverse events are gastrointestinal toxicities and the reversible elevation of liver enzyme levels. Nintedanib might also be combined with paclitaxel, carboplatin, pemetrexed and docetaxel. There are several ongoing clinical trials testing the efficacy of BIBF 1120.

KW - Angiogenesis

KW - BIBF 1120

KW - Receptor tyrosine kinase inhibitors

KW - Solid tumors

UR - http://www.scopus.com/inward/record.url?scp=84874414983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874414983&partnerID=8YFLogxK

M3 - Article

C2 - 23008829

AN - SCOPUS:84874414983

VL - 56

SP - 199

EP - 208

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 3

ER -